We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Read MoreHide Full Article
Key Takeaways
Omnicell raised 2026 adjusted EPS guidance to $2.15-$2.30 after second-quarter earnings beat estimates.
A $15 million tariff refund boosted OMCL's second-quarter EBITDA, but the one-time benefit will not recur.
Omnicell expects a $6 million memory-cost headwind as bookings and recurring revenue face timing delays.
Omnicell, Inc. (OMCL - Free Report) raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund.
The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive to hospital purchasing timelines.
Omnicell Lifted Its 2026 Earnings Outlook
Omnicell now expects adjusted earnings of $2.15-$2.30 per share for 2026, up from $1.80-$2.00 previously. Non-GAAP EBITDA guidance increased to $175-$185 million.
Second-quarter adjusted earnings reached 94 cents per share, up 108.9% year over year and 95.8% above the Zacks Consensus Estimate. Revenues rose 7.4% to $312.2 million and exceeded the consensus mark by 0.8%.
Based on short-term price targets offered by seven analysts, the average price target for Omnicell comes to $57.86. The average price target represents an increase of 55.83% from the last closing price.
Second-quarter non-GAAP EBITDA totaled $67 million, including a one-time $15 million refund of previously paid IEEPA tariffs. That benefit lifted product gross margin and earnings but will not recur.
Excluding the refund, non-GAAP EBITDA would have been $52 million. That still came in above the midpoint of prior guidance, indicating that the quarter’s underlying profitability was not solely dependent on the tariff benefit.
Omnicell Faces a $6 Million Memory Cost Headwind
Memory-chip supply-demand imbalance is expected to add about $6 million of incremental cost in the second half of 2026, roughly five times the level expected at the beginning of the year.
Management expects the pressure to reduce full-year consolidated gross margin by about 50 basis points and product gross margin by about 80 basis points. Continued component inflation or supply constraints could further limit margin expansion.
OMCL’s Cost Discipline Could Offset Some Pressure
Management attributed underlying second-quarter performance to revenue mix, cost control and operating efficiency. Those levers could help preserve earnings leverage as the tariff refund disappears and memory costs rise.
Hospital medication technology remains an active investment area. Becton, Dickinson and Company (BDX - Free Report) offers connected medication-management systems, including automated dispensing and inventory tools, while Baxter International Inc. (BAX - Free Report) markets connected infusion platforms used in medication delivery.
Omnicell’s Guidance Test Extends Beyond Margins
Full-year revenue guidance stands at $1.225-$1.245 billion. Omnicell also widened product-bookings guidance to $425-$560 million as management reassessed the timing of medium-sized and large health-system transactions.
Year-end annual recurring revenue guidance was reduced to $660-$680 million because certain consumables opportunities are taking longer to develop. A younger XT installed base and lengthy hospital approval cycles could also slow the timing of the Titan XT refresh.
In the past year, OMCL shares have risen 18.5% against the industry’s 15% decline.
Image Source: Zacks Investment Research
OMCL’s Ratings Frame the Event Risk
The raised earnings outlook improves the 2026 profit picture, but its durability depends on cost control, stable revenue conversion and the timing of larger customer decisions as input costs rise.
OMCL currently carries a Zacks Rank #5 (Strong Sell), alongside a Growth Score of A, Value Score of B, Momentum Score of B and VGM Score of A. The favorable Style Scores point to attractive growth, value and momentum characteristics, but the Zacks Rank remains the primary near-term signal and indicates unfavorable earnings-estimate revision trends.
View the Zacks #1 Rank List
Image: Bigstock
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Key Takeaways
Omnicell, Inc. (OMCL - Free Report) raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund.
The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive to hospital purchasing timelines.
Omnicell Lifted Its 2026 Earnings Outlook
Omnicell now expects adjusted earnings of $2.15-$2.30 per share for 2026, up from $1.80-$2.00 previously. Non-GAAP EBITDA guidance increased to $175-$185 million.
Second-quarter adjusted earnings reached 94 cents per share, up 108.9% year over year and 95.8% above the Zacks Consensus Estimate. Revenues rose 7.4% to $312.2 million and exceeded the consensus mark by 0.8%.
Based on short-term price targets offered by seven analysts, the average price target for Omnicell comes to $57.86. The average price target represents an increase of 55.83% from the last closing price.
Image Source: Zacks Investment Research
OMCL’s Tariff Refund Flattered Second-Quarter Profit
Second-quarter non-GAAP EBITDA totaled $67 million, including a one-time $15 million refund of previously paid IEEPA tariffs. That benefit lifted product gross margin and earnings but will not recur.
Excluding the refund, non-GAAP EBITDA would have been $52 million. That still came in above the midpoint of prior guidance, indicating that the quarter’s underlying profitability was not solely dependent on the tariff benefit.
Omnicell Faces a $6 Million Memory Cost Headwind
Memory-chip supply-demand imbalance is expected to add about $6 million of incremental cost in the second half of 2026, roughly five times the level expected at the beginning of the year.
Management expects the pressure to reduce full-year consolidated gross margin by about 50 basis points and product gross margin by about 80 basis points. Continued component inflation or supply constraints could further limit margin expansion.
OMCL’s Cost Discipline Could Offset Some Pressure
Management attributed underlying second-quarter performance to revenue mix, cost control and operating efficiency. Those levers could help preserve earnings leverage as the tariff refund disappears and memory costs rise.
Hospital medication technology remains an active investment area. Becton, Dickinson and Company (BDX - Free Report) offers connected medication-management systems, including automated dispensing and inventory tools, while Baxter International Inc. (BAX - Free Report) markets connected infusion platforms used in medication delivery.
Omnicell’s Guidance Test Extends Beyond Margins
Full-year revenue guidance stands at $1.225-$1.245 billion. Omnicell also widened product-bookings guidance to $425-$560 million as management reassessed the timing of medium-sized and large health-system transactions.
Year-end annual recurring revenue guidance was reduced to $660-$680 million because certain consumables opportunities are taking longer to develop. A younger XT installed base and lengthy hospital approval cycles could also slow the timing of the Titan XT refresh.
In the past year, OMCL shares have risen 18.5% against the industry’s 15% decline.
Image Source: Zacks Investment Research
OMCL’s Ratings Frame the Event Risk
The raised earnings outlook improves the 2026 profit picture, but its durability depends on cost control, stable revenue conversion and the timing of larger customer decisions as input costs rise.
OMCL currently carries a Zacks Rank #5 (Strong Sell), alongside a Growth Score of A, Value Score of B, Momentum Score of B and VGM Score of A. The favorable Style Scores point to attractive growth, value and momentum characteristics, but the Zacks Rank remains the primary near-term signal and indicates unfavorable earnings-estimate revision trends.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.